Open-Label Extension Study of Kuvan for Autism

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

December 31, 2011

Study Completion Date

March 31, 2012

Conditions
Autistic Disorder
Interventions
DRUG

Kuvan®

Brand-name Kuvan® (sapropterin) will be administered to all subjects at a dose of 20 mg/kg/day for 16 weeks.

Trial Locations (1)

94304

The Children's Health Council, Palo Alto

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

BioMarin Pharmaceutical

INDUSTRY

lead

The Children's Health Council

OTHER